BACKGROUND: The effect of specific antiretrovirals on inflammation is unclear. METHODS:A5224s was a substudy of A5202, which randomized HIV-infected treatment-naïve patients toblinded abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in a factorial design. Our analysis compared changes in inflammation markers from baseline to week 24 between ABC/3TC and TDF/FTC. Secondary analyses included changes at week 96 and comparisons of EFV vs. ATV/r. RESULTS: Analyses included 244 patients (85% male, 48% white non-Hispanic), median age 39 years, HIV-1 RNA 4.6 log10 copies/ml, CD4 240 cells/μl. TNF-α, soluble receptors of TNF-α (sTNFR)-I and II, soluble vascular cellular adhesion molecule (sVCAM)-1 and soluble intercellular adhesion molecule (sICAM)-1 decreased significantly at weeks 24 and 96, without significant differences between components (P ≥ 0.44). At week 24, ABC/3TC had a greater high-sensitivity C-reactive protein (hsCRP) mean fold change than TDF/FTC {1.43 vs. 0.88, estimated mean fold change percentage difference [Δ] 61.5% [95% confidence interval (CI) 13.6%, 129.5%]; P = 0.008}. Similar results were seen at week 96 (P = 0.021). At week 24 (but not 96), EFV had a greater hsCRP mean fold change than ATV/r [1.41 vs. 0.88; Δ = 60.2% (12.6%, 127.7%); P = 0.009]. IL-6 decreased significantly at week 24 with TDF/FTC but not with ABC/3TC (between-components P = 0.019). At week 96, IL-6 decreased significantly in both nucleoside reverse transcriptase inhibitor components (between-components P = 0.11). IL-6 changes were not significantly different between ATV/r and EFV at either time point (P ≥ 0.89). CONCLUSIONS:Soluble TNF-receptors and adhesion molecules decreased following treatment initiation and did not differ by regimens. Differences were seen on hsCRP and IL-6 changes with ABC/3TC vs. TDF/FTC and on hsCRP with EFV vs. ATV/r.
RCT Entities:
BACKGROUND: The effect of specific antiretrovirals on inflammation is unclear. METHODS: A5224s was a substudy of A5202, which randomized HIV-infected treatment-naïve patients to blinded abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in a factorial design. Our analysis compared changes in inflammation markers from baseline to week 24 between ABC/3TC and TDF/FTC. Secondary analyses included changes at week 96 and comparisons of EFV vs. ATV/r. RESULTS: Analyses included 244 patients (85% male, 48% white non-Hispanic), median age 39 years, HIV-1 RNA 4.6 log10 copies/ml, CD4 240 cells/μl. TNF-α, soluble receptors of TNF-α (sTNFR)-I and II, soluble vascular cellular adhesion molecule (sVCAM)-1 and soluble intercellular adhesion molecule (sICAM)-1 decreased significantly at weeks 24 and 96, without significant differences between components (P ≥ 0.44). At week 24, ABC/3TC had a greater high-sensitivity C-reactive protein (hsCRP) mean fold change than TDF/FTC {1.43 vs. 0.88, estimated mean fold change percentage difference [Δ] 61.5% [95% confidence interval (CI) 13.6%, 129.5%]; P = 0.008}. Similar results were seen at week 96 (P = 0.021). At week 24 (but not 96), EFV had a greater hsCRP mean fold change than ATV/r [1.41 vs. 0.88; Δ = 60.2% (12.6%, 127.7%); P = 0.009]. IL-6 decreased significantly at week 24 with TDF/FTC but not with ABC/3TC (between-components P = 0.019). At week 96, IL-6 decreased significantly in both nucleoside reverse transcriptase inhibitor components (between-components P = 0.11). IL-6 changes were not significantly different between ATV/r and EFV at either time point (P ≥ 0.89). CONCLUSIONS: Soluble TNF-receptors and adhesion molecules decreased following treatment initiation and did not differ by regimens. Differences were seen on hsCRP and IL-6 changes with ABC/3TC vs. TDF/FTC and on hsCRP with EFV vs. ATV/r.
Authors: Alan L Landay; John Spritzler; Harold Kessler; Donna Mildvan; Minya Pu; Larry Fox; Dorothy O'Neil; Barbara Schock; Daniel Kuritzkes; Michael M Lederman Journal: J Infect Dis Date: 2003-11-13 Impact factor: 5.226
Authors: Priscilla Y Hsue; Peter W Hunt; Elizabeth Sinclair; Barry Bredt; Arlana Franklin; Maudi Killian; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; David D Waters; Steven G Deeks Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Keith Henry; Douglas Kitch; Michael Dube; Robert Zackin; Robert A Parker; Dennis Sprecher; Scott Hammer; Judith Currier Journal: AIDS Date: 2004-12-03 Impact factor: 4.177
Authors: L Morabito; M C Montesinos; D M Schreibman; L Balter; L F Thompson; R Resta; G Carlin; M A Huie; B N Cronstein Journal: J Clin Invest Date: 1998-01-15 Impact factor: 14.808
Authors: Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange Journal: Arch Intern Med Date: 2006-01-09
Authors: Joseph G Feldman; Philip Goldwasser; Susan Holman; Jack DeHovitz; Howard Minkoff Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: Grace A McComsey; Douglas Kitch; Paul E Sax; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Eric S Daar Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Chris T Longenecker; Douglas Kitch; Paul E Sax; Eric S Daar; Camlin Tierney; Samir K Gupta; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Kristine Mace Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Kathleen M Melbourne; Belinda Ha; Grace A McComsey Journal: AIDS Date: 2014-06-19 Impact factor: 4.177